ThePeptide.expert
This information is for research and educational purposes only. This is not medical advice.
← All profiles
Cat 1 — 2026Metabolic

AOD-9604

Anti-Obesity Drug 9604 / hGH fragment 177-191

Fat-burning fragment of human growth hormone. Stimulates lipolysis without the anabolic or glucose effects of full GH. Completed Phase IIb human trials. Program paused vs GLP-1 competition.

Evidence
Human data exists
Routes
injectable, oral
Available since
Developed by Monash University Australia 1990s. Research use from 2000s. Phase IIb completed. Category 1 compounding access from February 2026.

Mechanism of action

Mimics the lipolytic region of GH via beta-3 adrenergic receptor stimulation and AMPK activation. Does NOT bind IGF-1 receptors so no muscle growth or blood glucose effects. Specifically targets visceral and subcutaneous fat metabolism through a different mechanism than GLP-1 drugs.

Effects in the body

AOD-9604 is GH's fat-burning function isolated and stripped of everything else. The anabolic and blood-sugar effects are absent making it potentially safer than full GH for metabolic research. Lower theoretical cancer concern than full GH due to absence of IGF-1R binding.

Pros & cons (from the literature)

Pros
  • Targets fat metabolism without anabolic effects
  • Does not elevate IGF-1 — lower cancer concern
  • Completed Phase IIb human clinical trial
  • Some oral bioavailability demonstrated
  • Cartilage repair data in addition to fat metabolism
Cautions
  • Phase III trials paused — modest efficacy vs GLP-1 drugs
  • Effects smaller than semaglutide or tirzepatide
  • Gray market versions often mislabeled
  • Limited large scale human evidence
  • Mechanism different from but less proven than GLP-1 class

Protocol summary (from published research)

Injectable 200-300 mcg per day subcutaneous in the morning on empty stomach. Oral form 1 mg capsule available though injection appears more effective. Short cycles typical.

Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.

FDA & regulatory status

Category 1 as of February 2026. Compoundable with physician prescription. Advanced through Phase IIb human trials by Metabolic Pharmaceuticals Australia. Program paused due to competitive GLP-1 landscape.

Evidence base

Phase IIb RCT completed showing statistically significant fat reduction vs placebo. Multiple published pharmacokinetic studies. No Phase III completion.

Primary research sources

Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.

Pro member exclusive

Significant savings on research-grade peptides at a licensed, quality-controlled supplier

Your Pro membership includes an exclusive discount code for 99%+ purity verified research peptides at the best available price, from a licensed supplier we have evaluated for purity standards and compliance. Plus curated guides so you know exactly what to research.

  • • Exclusive discount code included with Pro membership
  • • Curated guide for this specific peptide
  • • Verified 99%+ purity compounds
  • • Removes the guesswork entirely
Upgrade to Pro — $15/month

Cancel anytime · No long-term commitment

Important. ThePeptide.expert summarizes published research. We are not a pharmacy, do not prescribe, and make no therapeutic claims. Regulatory status varies by jurisdiction.